Азитромицин: современные аспекты клинического применения | КМАХ

Азитромицин: современные аспекты клинического применения

Клиническая Микробиология и Антимикробная Химиотерапия. 2006; 8(1):18-32

​ Веселов А.В., Козлов Р.С.
азитромицин фармакокинетика спектр активности показания к применению обзор
Раздел
Антимикробные препараты
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2006; 8(1):18-32

Аннотация

Открытие и внедрение в клиническую практику антибиотиков группы макролидов стало одним из крупнейших достижений в истории антимикробной терапии. Наиболее часто назначаемым макролидом является азитромицин, что связано с рядом его уникальных фармакокинетических и фармакодинамических свойств. Это позволило азитромицину на протяжении уже более 10 лет быть одним из самых востребованных макролидных антибиотиков при разных видах инфекционных заболеваний. В данном обзоре дана характеристика азитромицина с позиций клинической фармакологии и клинической микробиологии с учётом положений доказательной медицины, а также результатов его практического применения при широком спектре нозологических форм, включая использование в педиатрической практике.

  • 1. Omura S., editor. Macrolide Antibiotics. 2nd edition. Academic Press; 2002.
  • 2. Available from: http://www.imshealth.com.
  • 3. Blondeau J.M., DeCarolis E., Metzler K.L., Hansen G.T. The macrolides. Expert Opin Investig Drugs 2002; 11:189-215.
  • 4. Thibodeau K., Viera A. Atypical pathogens and challenges in community-acquired pneumonia. Am Fam Physician 2004; 69:1699-706.
  • 5. Genuis S.J, Genuis S.K. Managing the sexually transmitted disease pandemic: a time for reevaluation. Am J Obstet Gynecol 2004; 191:1103-12.
  • 6. Management of multiple drug-resistant infections. Edited by Gillespie S. Humana Press, 2004.
  • 7. Data available from: http://en.wikipedia.org/wiki/ Azithromycin.
  • 8. Drew R.H., Gallis H.A. Azithromycin – spectrum of activity, pharmacokinetics and clinical application. Pharmacother 1992; 12:161-73.
  • 9. Mendes C.M., Sinto S.I., Oplustil C.P., et al. In vitro susceptibility of gram-positive cocci isolated from skin and respiratory tract to azithromycin and twelve other antimicrobial agents. Braz J Infect Dis 2001; 5:269-76.
  • 10. Delmee M., Carpenter M., Glupczynski Y., et al. In vitro susceptibilities of 180 clinical isolates of Haemophilus influenzae to ampicillin, amoxicillin/clavulanate, cefaclor, cefuroxime, cefotaxime, clarithromycin and azithromycin. Acta Clin Belg 1996; 51:237-43.
  • 11. Gordillo M.E., Singh K.V., Murray B.E. In vitro activity of azithromycin against bacterial enteric pathogens. Antimicrob Agents Chemother 1993; 37:1203-5.
  • 12. Trautmann M., Riediger C., Moricke A., et al. Combined activity of azithromycin and lansoprazole against Helicobacter pylori. Helicobacter 1999; 4:113-20.
  • 13. Stout J.E., Sens K., Mietzner S. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing. Int J Antimicrob Agents 2005; 25:302-7.
  • 14. Renaudin H., Bebear C. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum. Eur J Clin Microbiol Infect Dis 1990; 9:838-41.
  • 15. Welsh L., Gaydos C., Quinn T.C. In vitro activities of azithromycin, clarithromycin, erythromycin and tetracycline against 13 strains of Chlamydia pneumoniae. Antimicrob Agents Chemother 1996; 40:212-4.
  • 16. Lefevre J.C., Escaffre M.C., Courdil M., Larens M.B. In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamydia trachomatis. Pathol Biol 1993; 41:313-5.
  • 17. Aydin D., Kucukbasmaci O., Gonullu N., Aktas Z. Susceptibilities of Neisseria gonorrhoeae and Ureaplasma urealyticum isolates from male patients with urethritis to several antibiotics including telithromycin. Chemotherapy 2005; 51:89-92.
  • 18. Ohrt C., Willingmyre G.D., Lee P., et al. Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob Agents Chemother 2002; 46:2518-24.
  • 19. Cantin L., Chamberland S. In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii. Antimicrob Agents Chemother 1993; 37:1993-6.
  • 20. Mortensen J.E., Rodgers G.L. In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella pertussis and Bordetella parapertussis. J Antimicrob Chemother 2000; 45(Suppl 1):47-9.
  • 21. Hunfeld K.P., Kraiczy P., Wichelhaus T.A., et al. Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates. Int J Antimicrob Agents 2000; 15:11-7.
  • 22. Bermudez L.E., Yamazaki Y. Effects of macrolides and ketolides on mycobacterial infections. Curr Pharm Des 2004; 10:3221-8.
  • 23. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34:482-92.
  • 24. Carbone C., Poole M.D. The role of newer macrolides in the treatment of community-acquired respiratory tract infections. A review of experimental and clinical data. J Chemother 1999; 11:107-18.
  • 25. Heilmann K., Beekmann S., Richter S., et al. Antimicrobial resistance with Streptococcus pneumoniae in 2003 – results of the Multinational GRASP Surveillance Program. Proceedings of 14th ECCMID, Prague, Czech Republic, 2004. Abstr. #P1130.
  • 26. Kozlov R.S., Appelbaum P.C., Kosowska K., et al. Results of multicenter study of antimicrobial resistance of nasopharyngeal Streptococcus pneumoniae in children from day-care centres and orphanages in Asian Russia (SPARS-ASIA study). Proceedings of 14th ECCMID, Prague, Czech Republic, 2004. Abstr. #P1146.
  • 27. Kosowska K., Kozlov R.S., Stratchounski L.S., Appelbaum P.C. Macrolide and quinolone resistance mechanisms in Streptococcus pneumoniae population from day-care centres and orphanages in Asian Russia. Proceedings of 14th ECCMID, Prague, Czech Republic, 2004. Abstr. #P1143.
  • 28. Козлов Р.С., Сивая О.В., Шпынев К.В. и соавт. Антибиотикорезистентность Streptococcus pyogenes в России: результаты многоцентрового проспективного исследования ПеГАС-I. Клиническая Микробиология и Антимикробная Химиотерапия 2005; 7:154-66.
  • 29. Richter S.S., Heilmann K.P., Beekmann S.E., et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 2005; 41:599-608.
  • 30. Reinert R., Felmingham D. Susceptibility of Streptococcus pyogenes to telithromycin and erythromycin: results from PROTEKT. Proceedings of 14th ECCMID, Prague, Czech Republic, 2004. Abstr. #P1088.
  • 31. Woo P.C., Lau S.K., Yuen K.-Y. Macrolides as immunomodulatory agents. Curr Med Chem - Anti-Inflammatory & Anti-Allergy Agents 2002; 1:131-41.
  • 32. Culic O., Erakovic V., Pamham M.J. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429: 209-29.
  • 33. Labro M.T., Abdelghaffar H. Immunomodulation by macrolide antibiotics. J. Chemother. 2001; 13:3-8.
  • 34. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004; 125:41S-51S.
  • 35. Uriate S.M., Molestina R.E., Miller R.D., et al. Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniae infection and tumor necrosis factor-alfa. J Infect Dis 2002; 185:1631-6.
  • 36. Tsai W.C., Rodriguez M.L., Young K.S., et al. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med 2004; 170:1331-9.
  • 37. Bosnar M., Kelneric Z., Munic V., et al. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob Agents Chemother 2005; 49:2372-7.
  • 38. Bell S.C., Senini S.L., McCormack J.G., et al. Macrolides in cystic fibrosis. Chron Respir Dis 2005; 2:85-98.
  • 39. Prescott W.A. Jr., Johnson C.E. Antiinflammatory therapies for cystic fibrosis: past, present, and future. Pharmacotherapy 2005; 25:555-73.
  • 40. Shitrit D., Bendayan D., Gidon S., et al. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 2005; 24:1440-3.
  • 41. Yates B., Murphy D.M., Forrest I.A., et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005; 172:772-5.
  • 42. Amsden G.W. Anti-inflammatory effects of macrolides – an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55:10-21.
  • 43. Ekici A., Ekici M., Erdemoglu A.K. Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma. J Asthma 2002; 39:181-5.
  • 44. Data available from: www.pfizer.com/download/uspi_zithromax.pdf.
  • 45. Lalak N.J., Morris D.L. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993; 25:370-4.
  • 46. Data available from: www.pfizer.com/pfizer/download/uspi_zithromaxIV.pdf.
  • 47. Thakker K.M., Caridi F., Powell M., Chung M. Multiple dose pharmacokinetics of azithromycin following 1 hour intravenous infusion in hospitalized patients with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 37:24.
  • 48. Hopkins S. Clinical toleration and safety of azithromycin in adults and children. Rev Contemp Pharmacother 1994; 5:383-9.
  • 49. Treadway G., Pontani D. Paediatric safety of azithromycin: worldwide experience. J Antimicrob Chemother 1996; 37(Suppl C):143-9.
  • 50. Data available from www.fda.gov.
  • 51. Periti P., Mazzei T., Mini E., Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23:106-31.
  • 52. Niederman M.S., Sarosi G.A., Glassroth J., Editors. Respiratory Infections. Lippincott Williams & Wilkins; 2nd edition, 2001.
  • 53. Swanson R.N., Lainez-Ventosilla A., De Salvo M.C., et al. Once-daily azithromycin for 3 days compared with clarithromycin for 10 days for acute exacerbation of chronic bronchitis: a multicenter, double-blind, randomized study. Treat Respir Med 2005; 4:31-9.
  • 54. Biebuyck X.A. and Azithromycin study group. Comparison of azithromycin and co-amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbation of chronic bronchitis in adults. J Int Med 1996; 24:407-18.
  • 55. DeAbate C.A., Mathew C.P., Warner J.H., et al. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir Med. 2000; 94:1029-37.
  • 56. Mertens J., van Barneveld P., Asin H., et al. Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbation of chronic bronchitis. Antimicrob Agents Chemother 1992; 36:1456-9.
  • 57. Mandell L., Bartlett J., Dowell S., et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37:1405-33.
  • 58. Gleason P., Meehan T., Fine J. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159:2562-72.
  • 59. Niederman M., Mandell L., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-54.
  • 60. Bosker G., Amin A., Emerman C.L., et al. Antibiotic Selection and Outcome-Effective Management of Community-Acquired Pneumonia: Year 2005 Update.
  • 61. Bradbury F. Comparison of azithromycin versus clarithromycin in the treatment of low respiratory tract infections. J Antimicrob Chemother 1993; 31:153-62.
  • 62. Drehobl M.A., De Salvo M.C., Lewis D.E., Breen J.D. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 2005; 128:2230-7.
  • 63. D’Ignazio J., Camere M.A., Lewis D.E., et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for the treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother 2005; 49:4035-41.
  • 64. Plouffe J., Schwartz D.B., Kolokathis A., et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. Antimicrob Agents Chemother 2000; 44:1796-802.
  • 65. Zervos M., Mandell L.A., Vrooman P.S., et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med 2004; 3:329-36.
  • 66. Niederman M.S., Craven D.E. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
  • 67. Hooton T.M. A comparison of azithromycin and penicillin V for the treatment of streptococcal pharyngitis. Am J Med 1991; 91:23S-26S.
  • 68. Casey J.R., Pichichero M.E. Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis. Clin Infect Dis 2005; 40:1748-55.
  • 69. Ioannidis J., Contopoulos-Ioannidis D., Chew P., Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections. J Antimicrob Chemother 2001; 48:677-89.
  • 70. Dunne M.W., Latiolais T., Lewis B., et al. Randomized, double-blind study of the clinical efficacy of 3 days of azithromycin compared with co-amoxiclav for the treatment of acute otitis media. J Antimicrob Chemother 2003; 52:469-72.
  • 71. Arguedas A., Emparanza P., Schwartz R.H., et al. A randomized, multicenter, double blind, double dummy trial of single dose azithromycin versus high dose amoxicillin for treatment of uncomplicated acute otitis media. Pediatr Infect Dis J 2005; 24:153-61.
  • 72. Casiano R.R. Azithromycin and amoxicillin in the treatment of acute maxillary sinusitis. Am J Med 1991; 91(Suppl A): 83-90.
  • 73. Clement P.A., de Gandt J.B. A comparison of the efficacy, tolerability and safety of azithromycin and co-amoxiclav in the treatment of sinusitis in adults. J Int Med Res 1998; 26:66-75.
  • 74. Murray J.J., Emparanza P., Lesinskas E., et al. Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults. Otolaryngol Head Neck Surg 2005; 133:194-200.
  • 75. Martin D.H., Mroczkowski T.F., Dalu Z.A., et al. A controlled trial of single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. N Engl J Med 1992; 327:921-5.
  • 76. Skerk V., Krhen I., Lisic M., et al. Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis. Int J Antimicrob Agents 2004; 24:188-91.
  • 77. Bevan C.D., Ridgway G.L., Rothermel C.D. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res 2003; 31:45-54.
  • 78. Habib A.R., Fernando R. Efficacy of azithromycin 1 g single dose in the management of uncomplicated gonorrhoea. Int J STD AIDS 2004; 15:240-2.
  • 79. Исследование АРГОН, НИИАХ СГМА, 2002-2004. Предварительные данные.
  • 80. Stratchounski L.S., Sekhin S.V., Voznesensky D.L., et al. Dramatic rise of resistance to fluoroquinolones in Neisseria gonorrhoeae in Central Russia. Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30 – Nov 2; Washington, DC, USA; p. 125, abst. C2-1887.
  • 81. Riedner G., Rusizoka M., Todd J., et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med 2005; 22:353:1236-44.
  • 82. Schmid G.P. Treatment of chancroid. Clin Infect Dis 1999; 28(Suppl 1):S14-20.
  • 83. Tan H.H., Chan R.K. An open label comparative study of azithromycin and doxycycline in the treatment of non-gonococcal urethritis in males and Chlamydia trachomatis cervicitis in female sex workers in an STD clinic in Singapore. Singapore Med J 1999; 40:519-23.
  • 84. O’Farrell N. Donovanosis. Sex Transm Infect 2002; 78:452-7.
  • 85. Parsad D., Pandhi R., Dogra S. A guide to selection and appropriate use of macrolides in skin infections. Am J Clin Dermatol 2003; 4:389-97.
  • 86. Daniel R. Azithromycin, erythromycin and cloxacillin in the treatment of infections of skin and associated soft tissues. European Azithromycin Study Group. J Int Med Res 1991; 19:433-45.
  • 87. Pierce M., Crampton S., Henry D., et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335:384-91.
  • 88. Centers for Disease Control and Prevention: 2002 Guidelines for Preventing Opportunistic Infections Among HIV-Infected Persons. MMWR 2002; 51:1-60.
  • 89. Rouse M.S., Steckelberg J.M., Brandt C.M., et al. Efficacy of azithromycin or clarithromycin for the prophylaxis of viridans group streptococcus experimental endocarditits. Antimicrob Agents Chemother 1997; 41:1673-6.
  • 90. European Society of Cardiology: Guidelines on Prevention, Diagnosis and Treatment of Infective Endocarditis. Eur Heart J 2004; 25:267-76.
  • 91. Frenck R.W., Mansour A., Nakhla I., et al. Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. Clin Infect Dis 2004; 38:951-7.
  • 92. Girgis N.I., Butler T., Frenck R.W., et al. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrob Agents Chemother 1999; 43:1441-4.
  • 93. Butler T., Girard A.E. Comparative efficacies of azithromycin and ciprofloxacin against experimental Salmonella typhimurium infection in mice. J Antimicrob Chemother 1993; 31:313-9.
  • 94. Sanchez R., Fernandez-Baca V., Diaz M.D., et al. Evolution of susceptibilities of Campylobacter spp. to quinolones and macrolides. Antimicrob Agents Chemother 1994; 38:1879-82.
  • 95. Yates J. Traveler’s diarrhea. Am Fam Physician 2005; 71:2095-100.
  • 96. Hardy W.D., Bozzette S., Safrin S., et al. Results from recent therapeutic trials for opportunistic infections from United States. AIDS 1994; 8:S15.
  • 97. Tabbara K.F., Hammouda E., Tawfik A., et al. Azithromycin prophylaxis and treatment of murine toxoplasmosis. Saudi Med J 2005; 26:393-7.
  • 98. Andersen S.L., Ager A., McGreevy P., et al. Activity of azithromycin as a blood schizonticide against rodent and human plasmodia in vivo. Am J Trop Med Hyg 1995; 52:159-61.
  • 99. Gingras B.A., Jensen J.B. Activity of azithromycin and erythromycin against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. Am J Trop Med Hyg 1992; 47:378-82.
  • 100. Tripathi R., Dhawan S., Dutta G.P. Blood schizontocidal activity of azithromycin and its combination with alpha/beta arteether against multi-drug resistant Plasmodium yoelii nigeriensis, a novel MDR parasite model for antimalarial screening. Parasitology 2005; 131:295-301.
  • 101. Dunne M.W., Singh N., Shukla M., et al. A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India. J Infect Dis 2005; 191:1582-8.
  • 102. Windsor J.J. Cat-scratch disease: epidemiology, aetiology and treatment. Br J Biomed Sci 2001; 58:101-10.
  • 103. Bass J.W., Freitas B.C., Freitas A.D., et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J 1998; 17:447-52.
  • 104. Hunfeld K.P., Kraiczy P., Wichelhaus T.A., et al. Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates. Int J Antimicrob Agents 2000; 15:11-7.
  • 105. Cameron D., Gaito A., Harris N., et al. Evidence-based guidelines for the management of Lyme disease. Expert Rev Anti Infect Ther 2004; 2(Suppl 1):S1-13.
  • 106. Malfertheiner P., Meagraud F., O’Morain C., et al. Current concepts in the management of Helicobacter pylori infection – The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16:167-80.
  • 107. Hulten K., Cars O., Hjelm E., Engstrand L. In vitro activity of azithromycin against intracellular Helicobacter pylori. J Antimicrob Chemother 1996; 37:483-9.
  • 108. Anagnostopoulos G.K., Kostopoulos P., Margantinis G., et al. Omeprazole plus azithromycin and either amoxicillin or tinidazole for eradication of Helicobacter pylori infection. J Clin Gastroenterol 2003; 36:325-8.
  • 109. Tindberg Y., Casswall T.H., Blennow M., et al. Helicobacter pylori eradication in children and adolescents by a once daily 6-day treatment with or without a proton pump inhibitor in a double-blind randomized trial. Aliment Pharmacol Ther 2004; 20:295-302.
  • 110. Iacopini F., Crispino P., Paoluzi O.A., et al. One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication. Dig Liver Dis 2005; 37:571-6.
  • 111. Sullivan B., Coyle W., Nemec R., Dunteman T. Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. Am J Gastroenterol 2002; 97:2536-9.
  • 112. Buck M.L. Pediatric therapy update: azithromycin. Pediatric Pharmacotherapy 2005; 11(4).
  • 113. Langley J.M., Halperin S.A., Boucher F.D., et al. Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics 2004; 114:96-101.
  • 114. Miron D., Torem M., Merom R., et al. Azithromycin as an alternative to nalidixic acid in the therapy of childhood shigellosis. Pediatr Infect Dis J 2004; 23:367-8.
  • 115. Frenck R.W., Mansour A., Nakhla I., et al. Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. Clin Infect Dis 2004; 38:951-7.
  • 116. Kapadia N., Talib A. Acne treated successfully with azithromycin. Int J Dermatol 2004; 43:766-7.
  • 117. Nahata M.C., Koranyi K.I., Gadgil S.D., et al. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. Antimicrob Agents Chemother 1993; 37:314-6.
  • 118. Nahata M.C., Koranyi K.I., Luke D.R., et al. Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. Antimicrob Agents Chemother 1995; 39:1875-7.
  • 119. Jacobs R.F., Maples H.D., Aranda J.V., et al. Pharmacokinetics of intravenously administered azithromycin in pediatric patients. Pediatr Infect Dis J 2005; 24:34-9.
  • 120. Ruuskanen O. Safety and tolerability of azithromycin in pediatric infectious diseases: 2003 update. Pediatr Infect Dis J 2004; 23:135-9.
  • 121. Регистр лекарственных средств России. Available from: www.rlsnet.ru.
  • 122. Azithromycin. Drug Facts and Comparisons. Efacts [online]. 2005. Available from Wolters Kluwer Health, Inc.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились